{"id":"tp-48439","type":"article-newspaper","title":"Corcept Ties $3B-$5B Cushing’s Revenue Outlook to Relacorilant","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/48439","datePublished":"2026-11-04T11:44:23.000Z","dateModified":"2026-11-04T11:44:23.000Z","language":"en","abstract":"The current Cushing’s syndrome business could generate at least $2 billion in annual revenue by decade’s end. The FDA is expected to decide on relacorilant by Dec. 17, 2026.","section":"Business","references":[]}